Journal ArticleDOI
Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
TLDR
The direct pricing strategy, i.e. the international reference pricing, was considered to be the most successful method in Norway after its accession to the European Economic Area (1994-2004), and due to the unpredictability of the market situation, the resulting effects of the indirect methods were more limited.About:
This article is published in Health Policy.The article was published on 2009-05-01. It has received 73 citations till now. The article focuses on the topics: Limit price & Price system.read more
Citations
More filters
Journal ArticleDOI
Pharmaceutical supply chain in China: current issues and implications for health system reform.
TL;DR: The root cause of the market and government failures is that higher-than-cost drugs preferred by all suppliers, and new drug pricing mechanism is the key to the current pharmaceutical reform and should be implemented in coordination with other health system reforms.
Journal ArticleDOI
The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview
TL;DR: As many pharmaceutical policies tend to address reimbursable medicines, generics fall under the scope of these measures, and European countries apply a mix of specifi c measures to promote generics uptake.
Journal ArticleDOI
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Sabine Vogler,Valérie Paris,Alessandra Ferrario,Veronika J. Wirtz,Kees de Joncheere,Peter Schneider,Hanne Bak Pedersen,Guillaume Dedet,Zaheer-Ud-Din Babar +8 more
TL;DR: There is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access in European countries, and increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.
Journal ArticleDOI
Generic substitution: additional challenge for adherence in hypertensive patients?
TL;DR: It is shown that generic substitution can be an additional factor in poor drug adherence in hypertensive patients and contributes to concerns and confusion among the patients.
Journal ArticleDOI
A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges?
TL;DR: Overall, the present study indicates that physicians and pharmacists are aware of the role of generic drugs in the improvement of global access to drugs, however, there are marked differences regarding how these health professionals view the quality ofGeneric drugs depending on the maturity of their country’s healthcare system.
References
More filters
Journal ArticleDOI
Pharmacological interventions for somatoform disorders in adults.
Maria Kleinstäuber,Michael Witthöft,Andrés Steffanowski,Harm W.J. van Marwijk,Wolfgang Hiller,Michael J. Lambert +5 more
TL;DR: A systematic review and meta-analysis of placebo-controlled studies examined the efficacy and tolerability of different types of antidepressants, the combination of an antidepressant and an antipsychotic, antipsychotics alone, or natural products in adults with somatoform disorders in adults to improve optimal treatment decisions.
Journal ArticleDOI
Interventions for latent autoimmune diabetes (LADA) in adults.
TL;DR: Two studies show SU leading to earlier insulin dependence and a meta-analysis of four studies with considerable heterogeneity showed poorer metabolic control if SU is prescribed for patients with LADA compared to insulin.
Posted Content
The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s
TL;DR: In this article, the authors analyzed the effect of pharmaceutical price regulation on delays in new drug launches in 25 major markets of 85 new chemical entities (NCEs) launched in the UK or US between 1994 and 1998.
Journal ArticleDOI
European Healthcare Policies for Controlling Drug Expenditure
TL;DR: European governments apply to reduce or at least slow down public expenditure on pharmaceutical products to target the industry, the wholesalers and retailers, prescribers, and patients is reviewed.
Journal ArticleDOI
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
TL;DR: In this article, the authors analyzed the effect of price regulation on delays in launch of new drugs in 25 major markets, including 14 EU countries, of 85 new chemical entities (NCEs) launched between 1994 and 1998.
Related Papers (5)
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
Patients' attitudes towards and experiences of generic drug substitution in Norway.
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
Brian Godman,William H. Shrank,Morten Andersen,Christian Berg,Iain Bishop,Thomas Burkhardt,Kristina Garuoliene,Harald Herholz,Roberta Joppi,Marija Kalaba,Ott Laius,Diane McGinn,Vita Samaluk,Catherine Sermet,Ulrich Schwabe,Inês Teixeira,Lesley Tilson,F. Cankat Tulunay,Vera Vlahović-Palčevski,Kamila Wendykowska,Björn Wettermark,Corinne Zara,Lars L. Gustafsson +22 more